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Abstract 
Context: Hormonal interventions in adolescents with gender dysphoria may have adverse effects, such 
as reduced bone mineral accrual.
Objective: To describe bone mass development in adolescents with gender dysphoria treated with 
gonadotropin-releasing hormone analogues (GnRHa), subsequently combined with gender-affirming 
hormones.
Design: Observational prospective study.
Subjects: 51 transgirls and 70 transboys receiving GnRHa and 36 transgirls and 42 transboys receiving 
GnRHa and gender-affirming hormones, subdivided into early- and late-pubertal groups.
Main Outcome Measures: Bone mineral apparent density (BMAD), age- and sex-specific BMAD z-scores, 
and serum bone markers.
Results: At the start of GnRHa treatment, mean areal bone mineral density (aBMD) and BMAD values were 
within the normal range in all groups. In transgirls, the mean z-scores were well below the population mean. 
During 2 years of GnRHa treatment, BMAD stabilized or showed a small decrease, whereas z-scores decreased 
in all groups. During 3  years of combined administration of GnRHa and gender-affirming hormones, a 
significant increase of BMAD was found. Z-scores normalized in transboys but remained below zero in 
transgirls. In transgirls and early pubertal transboys, all bone markers decreased during GnRHa treatment.
Conclusions: BMAD z-scores decreased during GnRHa treatment and increased during gender-affirming 
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transgirls had relatively low z-scores, both at baseline and after 3  years of estrogen treatment. It is 
currently unclear whether this results in adverse outcomes, such as increased fracture risk, in transgirls 
as they grow older.
Key Words:  bone mineral density, bone, GnRH analogue, sex steroids, gender dysphoria, transgender, adolescents
Over the last decades, children diagnosed with gender 
dysphoria have increasingly come to the attention of the 
psychomedical care system and clinicians recognize their 
suffering, aggravated by the somatic changes of puberty (1, 
2). The development of secondary sex characteristics can 
be temporarily halted with gonadotropin-releasing hor-
mone analogue (GnRHa) treatment (3). This offers the 
adolescent the opportunity to explore their wish to pursue 
gender-affirming treatment, while no longer experiencing 
the agonizing development of secondary sex character-
istics due to endogenous puberty, which are incongruent 
with gender identity. Birth-assigned girls must be at least in 
Tanner breast stage 2 with clear palpable mammary tissue, 
while birth-assigned boys must have reached Tanner stage 
G2 before initiating treatment with GnRHa (3, 4). If no 
contraindications exist, sex steroids consistent with the af-
firmed gender are added to the GnRHa treatment at an age 
where adolescents can give informed consent to such treat-
ment, usually at approximately 16 years (3). There is much 
discussion about this age, since 16 years is considered a late 
age to induce puberty in adolescents.
In young adults, peak bone mass (PBM) is higher in men 
than in women (5). Sex steroids play an essential role in 
the establishment of gender differences in bone mass, both 
through direct effects and indirect effects, for example, 
via differences in muscle mass and insulin-like growth 
factor (6). Puberty is an important period in determining 
adult bone mineral content (6). Together, these findings 
strengthen the notion that maximizing bone mineral ac-
crual during adolescence may be important in the preven-
tion of osteoporosis and fractures at older age.
One of the primary concerns when using GnRHa in 
adolescents for a prolonged period of time is the potential 
decrease in bone mineral density (BMD) (3, 7). The sup-
pression of the endogenous sex steroids to stop pubertal 
development, as recommended by current guidelines, may 
potentially interfere with the normal pubertal bone mass 
increment and reduce PBM. Therefore, assessment of BMD 
every 1 to 2 years is recommended (3). Three studies in ado-
lescents diagnosed with gender dysphoria receiving GnRHa 
and gender-affirming hormone treatment reported decreases 
in areal BMD (aBMD) and bone mineral apparent density 
(BMAD) z-scores during GnRHa treatment, although not 
all significant (8-10). Little difference was noted in change 
of BMAD z-scores between early- and late-pubertal groups 
as defined by bone age (8). Catch-up of bone mineral ac-
crual during subsequent gender-affirming hormone treat-
ment may be incomplete (8-10). One study investigated 
bone markers and showed a decrease of carboxyterminal 
cross-linked telopeptide of type I  collagen (1CTP) and 
N-terminal propeptide of type-1 collagen (P1NP) during 
GnRHa and during subsequent gender-affirming hormone 
treatment which was interpreted as evidence of decreased 
bone turnover (8). All these studies compared data at the 
start of GnRHa treatment, at the start of gender-affirming 
hormones and one endpoint, either 12–24 months after the 
start of gender-affirming hormone therapy or age 22 years. 
However, this does not provide information on the course 
of BMD during treatment. Do BMD z-scores continue 
to decline with prolonged use of GnRHa? How long do 
BMD z-scores continue to increase during GAH treatment? 
These questions remain unanswered. Now that increasing 
numbers of adolescents undergo this treatment, possibly 
starting at younger ages, there is a clear need for such 
data. Therefore we set out to describe the course of BMD 
during 2 years of GnRHa therapy and during 3 years of 
subsequent gender-affirming hormone treatment in a large 
group of adolescents diagnosed with gender dysphoria, 
with measurements at yearly intervals. We also investigated 
whether the outcome was influenced by the pubertal stage, 
as defined by Tanner stage, at which GnRHa treatment was 
started. In addition, we report data from a small subgroup 
with more prolonged GnRHa treatment.
Methods
Subjects and protocol
Subjects were adolescents fulfilling Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition, 
Text Revision (DSM-IV-TR) criteria for gender identity 
disorder (the term used at the time) (11) and eligible for 
treatment according to existing guidelines at that time (4, 
12, 13). The design of the study was observational and 
prospective, and individuals were included from 1998 
to 2009. The first phase of treatment consisted of intra-
muscular injections of GnRHa 3.75  mg (Triptorelin-CR 
(Ferring Pharmaceuticals, Denmark). The first 2 injections 
were administered with a 2-week interval followed by in-
jections every 4 weeks to suppress endogenous sex steroid 
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transgirls, oral estrogens were prescribed in an increasing 
dosage over a period of 2  years as previously described 
(4). Male puberty in transboys was induced by admin-
istering Sustanon (a mixture of testosterone propionate, 
-fenylpropionate, -isocaproate and -decanoate) intramus-
cularly in increasing doses over a period of 2 years (14). 
In subjects who were 16 years of age or older at the start 
of pubertal suppression, gender-affirming hormones were 
started at half the adult dose and increased to the adult 
dose after 6 months. A dose of 2 mg 17beta-estradiol per 
day and 125 mg testosterone-esters per 2 weeks was con-
sidered an adult dose. From 45 subjects, some data were 
also included in previous studies by Vlot et  al (8) and 
Klink et  al (10), but those studies only reported results 
at 3 time points: at the start of GnRHa, at the start of 
gender-affirming hormones, and after 2  years of gender-
affirming hormones (8) or age 22 years (10), and they did 
not describe a detailed course of BMD and bone markers 
over several years of GnRHa or gender-affirming hormone 
treatment.
Different effects of treatment might be expected de-
pending on the pubertal stage at baseline. A previous study 
used a bone age cutoff of 14 and 15 years for transboys and 
transgirls, respectively, to define early- and late-pubertal 
groups (8). However, especially for transboys, bone age 
14 years signifies the final stages of puberty and near com-
pletion of linear growth rather than midpuberty. In the 
current study, Tanner stage was used to define early- and 
late-pubertal groups, with the early-pubertal group defined 
as Tanner stage 2 or 3 at the start of GnRHa treatment, and 
the late-pubertal group as Tanner stage 4 or 5.
Bone densitometry
Dual-energy x-ray absorptiometry (DXA) was performed 
before GnRHa administration and then every subsequent 
year using Hologic QDR 4500 (Holologic Inc., Waltham, 
MA, USA). Likewise, at the start of gender-affirming hor-
mone treatment, a DXA scan was performed, with yearly 
measurements thereafter. Areal BMD (aBMD, g/cm2) of the 
lumbar spine, nondominant hip, and whole body, as well as 
the bone mineral content of the whole body (BMC-WB, g) 
were measured. To calculate z-scores based on age and sex, 
the National Health and Nutrition Examination Surveys 
(NHANES) references values were used. Because changes 
in aBMD might partly be due to altered growth during 
treatment, we also studied BMAD (g/cm3) calculated as de-
scribed by Ward et al (15). BMAD z-scores were calculated 
using LMS data from an English reference population (15). 
To calculate z-scores the reference population of the birth-
assigned sex was used. For adolescents older than 17 years 
no reference values of BMAD are available; therefore, 
reference values of 17 year-olds were used to calculate the 
z-score at older ages (15).
Serum bone markers
Markers of bone formation (P1NP, P3NP, and osteocalcin) 
and of bone resorption (1CTP) were determined in fasting 
blood samples, drawn before noon on the same days as the 
DXA scans, and stored at −20 °C.
Osteocalcin was measured by an immunometric assay 
(Colorimetric, BioSource, Nivelles, Belgium) (lower detec-
tion limit of 0.4 nmol/L; inter-assay coefficient of variation 
(CV) for the whole range <10%). Serum 1CTP, P1NP, and 
P3NP levels were measured using a radioimmunoassay 
(Orion Diagnostica, Espoo, Finland). The lower ranges of 
detection were 1 µg/L for 1CTP, 5 µg/L for P1NP, and 1µg/L 
for P3NP. The inter-assay CV for the whole range of 1CTP 
was 7% and for P1NP 8%. The CV for P3NP was 6% at 
4.2 µg/L and 8% at 6.2 µg/L.
Statistical analyses
Independent t tests were used to ascertain differences be-
tween the ages of the transgirls and transboys. To analyze 
changes in BMAD over time, data were analyzed using a 
linear mixed model. A full factorial model was chosen as 
fixed part of the model, ie, a model consisting of time (3 or 
4 levels), pubertal stage (early/late), and sex and all possible 
interactions (ie, three 2-way and one 3-way interactions). 
An unstructured covariance matrix was used as random 
part of the model. An advantage of the linear mixed model 
approach above traditional repeated measurements ana-
lysis of variance (ANOVA) is that all acquired data are 
included in the analyses and no data are lost due to incom-
plete data sets.
Differences in aBMD during a more prolonged period 
of GnRHa treatment were calculated using the related sam-
ples Wilcoxon Signed Ranked test.
All data on BMAD, and z-scores are presented as es-
timated marginal means and standard error of the mean. 
The statistical package was SPSS 22.0 (SPSS Inc., Chicago, 
IL, USA).
Ethical approval
The study was placed on the International Standard 
Randomized Controlled Trial Number register and 
ascribed registration number ISRCTN 81574253 (www.
isrctn.com). Approval by the local medical ethical com-
mittee was obtained. Informed consent for the study was 
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Results
A total of 54 transgirls and 73 transboys started treat-
ment according to this protocol. For 51 transgirls and 70 
transboys, DXA scans were available at the start of GnRHa 
administration and these individuals were included in the 
analyses. There were no significant differences between 
the ages of the transgirls and the transboys at the start of 
GnRHa administration (Table 1).
A total of 36 transgirls and 42 transboys received 
gender-affirming hormone treatment in addition to GnRHa 
treatment. The transboys were slightly but significantly 
older at start of gender-affirming hormone treatment than 
the transgirls (Table 1). The ratio of subjects who were in 
early and in late puberty was not different in the group 
evaluated for the effects of gender-affirming hormone treat-
ment compared with the group analyzed during GnRHa 
treatment alone.
Anthropometric data and data on pubertal development 
of the subjects at baseline are shown in Table 1. All ado-
lescents had sex characteristics typical of the sex assigned 
at birth and none had signs of a difference/disorder of sex 
development. None of the adolescents had a bone fracture 
during the study.
Changes during 2 years of GnRHa treatment
Bone mineral apparent density. Changes in aBMD and 
aBMD z-scores are shown in Table 2. BMAD of the lumbar 
spine did not change during 2 years of GnRHa treatment 
in the transgirls or the early pubertal transboys (P = 0.84, 
P = 0.09, and P = 0.69, respectively) (see Fig. 1, Table 2). In 
the late-pubertal transboys, a small but significant decrease 
in BMAD of the lumbar spine was found.
BMAD of the femoral neck showed a significant de-
crease in the late-pubertal transgirls and in both groups of 
transboys (P = 0.007, P = 0.015, and P < 0.001, respect-
ively) (see Fig. 1, Table 2). The small decrease in the early 
pubertal transgirls was not significant (P = 0.31).
Bone mineral apparent density z-scores. At the start, 
z-scores of the BMAD at both locations were higher in 
the transboys than in the transgirls. The BMAD z-score 
of the lumbar spine significantly decreased in all 4 groups 
(P ≤ 0.001) (see Fig. 1, Table 2). The BMAD z-scores of 
the femoral neck significantly decreased in all groups 
(P = 0.006, P = 0.002, and P < 0.001) except for the 
early-pubertal transgirls (P = 0.25). Four transgirls had 
a z-score of the hip below −2 after 2  years of GnRHa 
treatment and 3 individuals had a z-score of the lumbar 
spine below −2. Two transboys had a z-score of the hip 
below −2 whereas none of the transboys had a z-score 
of the lumbar spine below −2 after 2  years of GnRHa 
treatment.
Bone mineral density during prolonged GnRHa treatment.
Because the average age at the start of GnRHa treat-
ment was more than 14  years, most individuals 
were not treated with GnRHa for more than 2  years 
Table 1. Characteristics at the Start of GnRHa Treatment and at the Start of Gender-Affirming Hormone Treatment
Start GnRHa Transgirls (n = 51) Transboys (n = 70) P value
Age in years, mean ± SD 14.1 ± 1.7 14.5 ± 2.0 n.s.
Pubertal group: Early/late 15/36 14/56 n.s.
Height in cm, mean ± SD 169.0 ± 8.9 162.2 ± 8.8 <0.001
Weight in kg, mean ± SD 57.9 ± 12.9 56.2 ± 14.7 n.s.
BMI in kg/m2, mean ± SD 20.1 ± 3.3 21.3 ± 4.2 n.s.




Serum testosterone  
in nmol/L, median [IQR]





 Transgirls (n = 36) Transboys (n = 42)  
Age in years, mean ± SD 16.2 ± 1.2 16.9 ± 1.1 0.005
Pubertal group: Early/late 10/26 5/37 n.s.
Duration of GnRHa use before start GAH, 
years
2.0 ± (0.94) 1.8 ± (1.11) n.s.
Height in cm, mean ± SD 176.5 ± 7.3 167.1 ± 7.4 0.005
Weight in kg, mean ± SD 66.7 ± 11.9 63.5 ± 11.5 n.s.
BMI in kg/m2, mean ± SD 21.1 ± 3.2 22.8 ± 4.0 n.s.
Abbreviations: BMI, body mass index; GAH, gender-affirming hormones; GnRHa, gonadotropin-releasing hormone analogue; IQR, interquartile range; n.s., not 
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before gender-affirming hormone treatment was started. 
However, a few younger individuals were treated for up 
to 4 years. The aBMD values of the lumbar spine and hip 
in 4 transboys and 11 transgirls remained stable during 
3 years of GnRHa treatment. The z-scores on the other 
hand declined (Table 3).
Serum bone markers. At baseline, there were no significant 
differences in serum levels of any of the 4 bone markers 
(P1NP, P3NP, osteocalcin, 1CTP) between the early- and 
late-pubertal groups of transgirls (Fig. 2). In the transboys, 
baseline serum levels of all 4 bone markers were significantly 
higher in those in early puberty compared to those in later 
puberty.
After 2 years of GnRHa treatment serum levels of all 4 
bone markers showed a significant decrease in both groups 
of transgirls and in early-pubertal transboys, which was 
most marked during the first year of treatment (Fig.  2). 
Serum levels of P3NP and 1CTP showed a smaller but sig-
nificant decrease in late-pubertal transboys whereas serum 
levels of P1NP and osteocalcin did not change in this group.
Changes during 3 years of gender-affirming 
hormone treatment
After an average of 1.89  years (± 1.03  year) of GnRHa 
administration, gender-affirming hormones were added to 
the treatment. Both early-pubertal groups were on GnRHa 
for a significantly longer time (2.5 years in transgirls (n = 7) 
and 4.0  years in transboys (n = 3)) when compared with 
both late-pubertal groups (1.5  years in transgirls and 
1.7 years in transboys) (P < 0.001).
Bone mineral apparent density. Changes in aBMD and 
aBMD z-scores are shown in Table 4. A significant increase 
in BMAD of the lumbar spine was found in all 4 groups 
Table 2. aBMD and BMAD During 2 Years of GnRHa Treatment
Transgirls
Early Pubertal Late-Pubertal
0 mo 24 mo 0 mo 24 mo p1 p2
aBMD_LS g/cm2 0.73 (0.03) 0.75(0.03) 0.79 (0.02) 0.82 (0.02) <0.05 <0.05
Z-score −0.67 (0.26) −1.26 (0.24) −0.33 (0.17) −0.92 (0.17) <0.05 <0.05
aBMD_hip g/cm2 0.81 (0.03) 0.86 (0.03) 0.87 (0.02) 0.89 (0.02) <0.05 n.s.
Z-score −0.49 (0.24) −0.93 (0.21) −0.43 (0.16) −1.01 (0.15) <0.05 <0.05
Whole body BMD g/cm2 0.90 (0.02) 0.92 (0.02) 0.95 (0.01) 0.95 (0.01) <0.05 n.s.
Z-score −0.56 (0.24) −1.51 (0.20) −0.51 (0.16) −1.62 (0.15) <0.05 <0.05
BMAD_LS g/cm3 0.20 (0.01) 0.20 (0.01) 0.20 (0.01) 0.21 (0.0!) n.s. n.s.
Z-score −0.33 (0.33) −1.19 (0.34) −0.65 (0.20) −1.21 (0.22) <0.05 <0.05
BMAD_hip g/cm3 0.28 (0.01) 0.27 (0.01) 0.28 (0.01) 0.26 (0.01) n.s. <0.05
Z-score −0.94 (0.27) −1.23 (0.35) −1.01 (0.17) −1.56 (0.25) n.s. <0.05
Transboys
Early-pubertal Late-pubertal
0 mo 24 mo 0 mo 24 mo p1 p2
aBMD_LS g/cm2 0.75 (0.03) 0.80 (0.03) 0.95 (0.01) 0.92 (0.01) <0.05 <0.05
Z-score −0.28 (0.27) −1.04 (0.26) 0.38 (0.14) −0.71 (0.14) <0.05 <0.05
aBMD_hip g/cm2 0.79 (0.03) 0.83 (0.03) 0.93 (0.01) 0.89 (0.02) <0.05 <0.05
Z-score 0.09 (0.26) −0.50 (0.24) 0.46 (0.13) −0.56 (0.13) <0.05 <0.05
Whole body BMD g/cm2 0.88 (0.02) 0.92 (0.02) 1.03 (0.01) 1.01 (0.01) <0.05 <0.05
Z-score −0.28 (0.27) −0.82 (0.24) 0.66 (0.13) −0.40 (0.13) <0.05 <0.05
BMAD_LS g/cm3 0.22 (0.01) 0.22 (0.01) 0.25 (0.01) 0.24(0.01) n.s. <0.05
Z-score −0.15 (0.29) −0.86 (0.30) 0.33 (0.14) −0.56 (0.17) <0.05 <0.05
BMAD_hip g/cm3 0.30 (0.01) 0.28 (0.01) 0.32 (0.01) 0.30 (0.01) <0.05 <0.05
Z-score −0.23 (0.25) −0.94 (0.30) 0.04 (0.12) −0.54 (0.18) <0.05 <0.05
aBMD and BMAD during 2 years of GnRHa treatment. Values are presented as estimated marginal means ± standard error. p1 represents the P value between the 
start and after 2 years of treatment for the early pubertal groups. p2 represents the P value between start and after 2 years of treatment for the late-pubertal groups. 
For changes per year of treatment see Fig. 1.
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(P < 0.001) after 3  years of gender-affirming hormone 
treatment (Fig. 3, Table 4). The BMAD of the femoral neck 
showed a significant increase in both groups of transgirls 
and in the early-pubertal transboys (P < 0.05). In the late-
pubertal transboys the increase was not significant.
Bone mineral apparent density z-scores. The BMAD 
z-scores of the lumbar spine significantly increased in all 
4 groups (Fig.  3, Table  4). Z-scores of the femoral neck 
showed a significant increase in both groups of transgirls 
and in the early pubertal transboys. The increase of the 
z-score in late-pubertal transboys was not significant.
Three transgirls had a z-score of the femoral neck below 
−2 and 3 individuals had a z-score of the lumbar spine 
below −2 after 3 years of gender-affirming hormone treat-
ment. None of the transboys had a z-score below −2 after 
3 years of gender-affirming hormone treatment.
Serum bone markers. The mean serum levels of the bone 
markers prior to gender-affirming hormone administration 
are shown in Fig. 4. Serum levels of P1NP, P3NP, and 1CTP 
were significantly higher in the early pubertal transgirls 
than in the late-pubertal transgirls. In the transboys, 
baseline serum levels of P1NP and P3NP were significantly 
higher in the early pubertal group compared with the late-
pubertal group. Levels of all 4 markers changed little in 
the late-pubertal transboys, whereas in the early pubertal 
transboys and late-pubertal transgirls, osteocalcin, P1NP, 
and P3NP showed a pronounced decrease during the 
first year of gender-affirming hormone treatment, after 
which levels stabilized. Remarkably, in the early-pubertal 
transgirls an initial increase in the P1NP, P3NP, and 1CTP 
levels was found followed by a decrease. After 3 years of 
gender-affirming hormone treatment, all 4 bone markers 
had significantly decreased in both early and late-pubertal 
transgirls. In transboys, osteocalcin, P1NP, and 1CTP 
significantly decreased. In both early and late-pubertal 
transboys, serum levels of P3NP did not significantly change.
Discussion
This study examined the impact of puberty suppression 
and subsequent addition of gender-affirming hormones 
Figure 1. Estimated marginal means and standard error of the mean of BMAD prior to and during 2 years of GnRHa administration in transgirls and 
transboys. Significant changes during the 2 years of GnRHa administration are indicated by an asterisk. Abbreviations: BMAD: bone mineral ap-
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Table 3. aBMD and aBMD Z-Scores During 3 Years ofGnRHa Treatment




Start 12 Months 24 Months 36 Months P
Transgirls 12.6  
(12.1-12.8)
3.45 (0.43) aBMD LS (g/cm^2) 
mean(± SD) (n = 4)
0.73 (0.9) .74 (0.10) 0.77 (0.11) 0.77 (0.11) 0.14
Z-score LS mean  
(± SD) (n = 4)
−0.43 (1.41) −0.92 (1.40) −1.05 (1.31) −1.15 (1.00) 0.07
aBMD Hip (g/ 
cm^2) mean  
(± SD) (n = 4)
0.80 (0.04) 0.82 (0.4) 0.83 (0.05) 0.85 (0.06) 0.07
Z-score hip mean  
(± SD) (n = 4)
−0.18 (0.50) −0.65 (0.34) −1.08 (0.42) −1.08 (0.42) 0.007
Transboys 12.7  
(11.9-14.0)
3.30 (0.50) aBMD LS (g/cm^2) 
mean (± SD) (n)
0.85 (0.13) (11) 0.88 (0.10) (11) 0.90 (0.11) (11) 0.90 (0.9) (11) 0.29
Z-score LS mean  
(± SD) (n)
0.42 (1.01) (9) −0.52 (0.83) (10) −0.35 (0.96) (11) −0.53 (0.78) (11) 0.008
aBMD Hip (g/ 
cm^2) mean  
(± SD) (n)
0.88 (0.09) (9) 0.88 (0.71) (11) 0.87 (0.08) (11) 0.88 (0.09) (11) 0.95
Z-score hip mean  
(± SD) (n)
0.86 (0.71) (8) 0.40 (0.71) (8) −0.18 (0.67) (9) −0.30 (0.67) (10) 0.12
Abbreviations: aBMD, areal bone mineral density; LS, lumbar spine; SD, standard deviation.
Figure 2. Estimated marginal means and negative standard error of the mean of osteocalcin, P1NP, P3NP, and 1CTP prior to and during 2 years of 
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on bone development in adolescents diagnosed with 
gender dysphoria. At the start of GnRHa treatment, 
aBMD and BMAD values were within the normal range. 
However, transgirls had z-scores well below zero, whereas 
these were close to zero in transboys. This finding is con-
sistent with previous studies (8, 10, 16-18) and may be 
explained by differences in lifestyle and exercise inten-
sity between transgirls and transboys. A  recent study 
showed that high-school transgirls have a higher intake 
of fast-food and are less physically active than transboys 
(19). In a different cohort of transgender adolescents we 
found vitamin D levels <50 nmol/L in 74% of transboys 
and 78% of transgirls starting GnRHa treatment ((9) 
and unpublished data). However, these findings do not 
explain why BMD z-scores are lower in transgirls than 
in transboys. Alternatively, it may be hypothesized that 
biological factors that act during intrauterine or early 
development and are involved in the development of 
gender dysphoria, are also related to bone development 
programming. For example, a whole-exome sequencing 
study in transgender individuals found 21 variants in 
19 genes associated with estrogen activated pathways of 
sexually dimorphic brain development (20). These vari-
ants in estrogen receptor–activated pathways might also 
play a role in bone mineral acquisition.
During GnRHa treatment we observed a decline of 
aBMD and BMAD z-scores in line with previous studies 
(8-10). In transgirls a decrease of aBMD z-scores was also 
reported with the use of the anti-androgenic progestin 
cyproterone acetate (18). In contrast, 1 study showed that 
in transboys treated with the progestin lynestrenol for an 
average of 11.6 months aBMD z-scores were stable or in-
creased (18). If these results are confirmed, also with more 
prolonged treatment duration, the better safety profile with 
regard to bone health is an important point to discuss with 
adolescents. In particular, older transboys who have already 
Table 4. aBMD and BMAD During 3 Years of Gender-Affirming Hormone Treatment in Addition to GnRHa Treatment
Transgirls
Early-Pubertal Late-Pubertal  
0 36 0 36 p1 p2
aBMD_LS g/cm2 0.77 (0.03) 0.95 (0.04) 0.83 (0.02) 0.95 (0.03) <0.05 <0.05
Z-score −1.37 (0.30) −0.82 (0.39) −0.99 (0.19) −1.05 (0.25) <0.05 n.s.
aBMD_hip g/cm2 0.87 (0.03) 1.02 (0.04) 0.88 (0.02) 0.96 (0.02) <0.05 <0.05
Z-score −0.99 (0.23) −0.09 (0.28) −0.86 (0.14) −0.70 (0.18) <0.05 n.s.
Whole body BMD g/cm2 0.93 (0.02) 1.06 (0.06) 0.96 (0.01) 0.98 (0.04) <0.05 n.s. 
Z-score −1.67 (0.23) −1.22 (0.28) −1.42 (0.14) −1.48 (0.18) <0.05 n.s.
BMAD_LS g/cm3 0.20 (0.08) 0.24 (0.09) 0.21 (0.05) 0.24 (0.06) <0.05 <0.05
Z-score −1.39 (0.36) −0.49 (0.40) −1.29 (0.23) −0.50 (0.25) <0.05 <0.05
BMAD_hip g/cm3 0.28 (0.01) 0.31 (0.02) 0.27 (0.01) 0.27 (0.01) <0.05 <0.05
Z-score −0.88 (0.23) −0.35 (0.37) −1.36 (0.20) −1.21 (0.24) <0.05 <0.05
Transboys
 Early-pubertal Late-pubertal  
0 36 0 36 p1 p2
aBMD_LS g/cm2 0.82 (0.04) 1.02 (0.07) 0.90 (0.02) 0.99 (0.02) <0.05 <0.05
Z-score −1.30 (0.43) 0.11 (0.58) −0.68 (0.16) −0.26 (0.22) <0.05 <0.05
aBMD_hip g/cm2 0.83 (0.04) 1.02 (0.06) 0.88 (0.02) 0.96 (0.02) <0.05 <0.05
Z-score −0.82 (0.33) 0.59 (0.43) −0.50 (0.12) 0.12 (0.16) <0.05 <0.05
Whole body BMD g/cm2 0.94 (0.03) 1.11 (0.10) 1.02 (0.01) 1.10 (0.03) n.s. <0.05
Z-score −1.06 (0.32) 0.21(0.43) −0.30 (0.12) −0.05 (0.16) <0.05 <0.05
BMAD_LS g/cm3 0.22(0.01) 0.26 (0.01) 0.24 (0.01) 0.26 (0.01) <0.05 <0.05
Z-score −1.01 (0.49) 0.12 (0.51) −0.61 (0.18) −0.04 (0.18) <0.05 <0.05
BMAD_hip g/cm3 0.28 (0.02) 0.32 (0.02) 0.30 (0.01) 0.32 (0.01) <0.05 n.s.
Z-score −0.71 (0.37) 0.01 (0.43) −0.41 (0.14) −0.10 (0.16) <0.05 n.s. 
aBMD and BMAD during 3 years of GnRHa plus gender-affirming hormone treatment. Values are presented as estimated marginal means ± standard error. p1 
represents the P value between start and after 3 years of treatment for the early-pubertal groups. p2 represents the P value between start and after 3 years of treat-
ment for the late-pubertal groups. 
For changes per year of treatment see Fig. 2.
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completed breast development may prefer lynestrenol to 
GnRHa treatment.
In most individuals with prolonged (3-4 years) GnRHa 
treatment, no further decrease in aBMD z-scores was ob-
served in the last year, suggesting that z-scores might sta-
bilize. Data from a larger cohort of adolescents treated 
with GnRHa for longer periods of time are needed, es-
pecially now that adolescents are presenting at younger 
ages at gender identity clinics and starting treatment at the 
onset of puberty.
During gender-affirming hormone treatment, a signifi-
cant increase in the BMAD of the lumbar spine was found 
in all groups, and of the femoral neck in all but the late-
pubertal transboys. In line with previous studies, BMAD 
z-scores were close to zero in transboys after 3  years of 
testosterone treatment (8-10). The increase in z-scores was 
most pronounced in the early pubertal transboys whose 
z-scores were slightly higher after 3  years of androgen 
treatment than at the start of GnRHa treatment.
The BMAD z-scores remained well below zero in 
transgirls in line with previous studies (8, 10). However, 
BMAD z-scores in early-pubertal transgirls increased more 
during estrogen treatment and were higher after 36 months 
than the scores reported by Vlot et al after 24 months (8). 
This might be due to the extra year of estrogen treatment 
in the current study, although the z-score of BMAD at the 
femoral neck no longer seemed to increase between 24 and 
36 months. In contrast, the BMAD z-scores of the femoral 
neck in the late-pubertal transgirls were much lower after 
36 months in the current study than previously reported 
(8). This may be due to the lower z-scores at the start of 
GnRHa treatment (−1.01 vs −0.44) and at the start of es-
trogen treatment (−1.36 vs −0.36) in the current study com-
pared with the study by Vlot et al.
An important limitation of this study is the lack of 
an untreated control group. As discussed above, z-scores 
in transgirls were already well below 0 at the start of 
treatment, and these might have further decreased even 
without treatment, as low BMD was also observed in adult 
transwomen before the start of any treatment (16, 17).
Another issue is which reference population should be used 
to calculate BMD or BMAD z-scores. In transgirls who started 
treatment in early puberty, bone architecture may be more 
similar to that of cisgender females than to cisgender males. 
A recent study did not find changes in cortical bone geometry 
in response to estrogen treatment in adult transwomen, but 
the authors suggested that this might have been different if 
they had started treatment during puberty (21).
Figure 3. Estimated marginal means and standard error of the mean of BMAD prior to and during 3 years of GnRHa + gender-affirming treatment in 
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GnRHa are not only used in transgender children, but 
also in other populations, mainly in children with preco-
cious or early puberty. A recent publication from an inter-
national consortium on the use of GnRHa concluded from 
the available evidence in this group that the treatment was 
safe with regard to bone mineral density, with attenuated 
bone mineral accrual reported during treatment but re-
covery by late adolescence (22). Different findings in chil-
dren with precocious puberty compared with transgender 
adolescents may be due to the different timing of GnRHa 
treatment, the use of gender-affirming hormones, with cur-
rent estradiol dose possibly insufficient (23), versus en-
dogenous puberty, and due to differences in baseline BMD 
between the groups.
In transgirls and early-pubertal transboys, all bone 
markers decreased during the first year of GnRHa treat-
ment while BMD levels remained stable. However, in the 
late-pubertal transboys bone turnover markers were lower 
at baseline and did not change. This suggests that the decline 
of the bone markers during GnRHa treatment may not be 
due to reduced bone mineral accrual but may rather reflect 
reduced growth velocity after initiating treatment. The late-
pubertal transboys had likely already reached (near) adult 
height, which could explain the lower and stable levels of 
bone turnover markers. We previously observed a similar 
decrease of alkaline phosphatase during GnRHa treatment, 
but only in those who had not yet completed growth (24). 
The opposite effect was seen during the first year of treat-
ment with gender-affirming hormones, where bone markers 
increased in the early pubertal transgirls, who likely had 
most growth potential. In adults, changes in P1NP were 
also found to be only weakly correlated to changes in BMD 
in transwomen and not significantly correlated in transmen 
(25). A previous study of bone turnover markers in ado-
lescents observed a similar pattern of changes in P1NP 
and 1CTP to the current study (8). However, changes in 
osteocalcin were only seen in late-pubertal transboys, pos-
sibly due to the small number of subjects in that study 
with large interindividual differences in the changes of 
osteocalcin levels (8).
Based on the current study we propose that it is suf-
ficient to perform DXA scans at the start of GnRHa 
Figure 4. Estimated marginal means and standard error of the mean of osteocalcin, P1NP, P3NP, and 1CTP prior to and during 3 years of GnRHa + 
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treatment, every 2  years during GnRHa treatment, at 
the start of gender-affirming hormone treatment, and 
then every 2 to 3  years. Adolescents should be coun-
seled on the importance of weight-bearing exercise, an 
adequate dietary calcium intake, sufficient sunlight ex-
posure to ensure adequate vitamin D levels, or vitamin 
D supplementation (26). In addition, it is important to 
ensure an adequate estrogen dose resulting in physio-
logical serum estradiol levels. Routine measurement of 
bone turnover markers does not seem to be useful for 
monitoring bone health.
In conclusion, treatment with GnRHa results in a sta-
bilization and maintenance of previously achieved bone 
mass in the lumbar spine but a small decrease in BMAD 
of the femoral neck of the nondominant hip. Gender-
affirming hormone treatment increases bone accretion and 
normalizes the age- and sex-specific BMAD z-scores in 
transboys. Transgirls had lower BMAD z-scores, especially 
the late-pubertal group, but as z-scores were already lower 
at baseline, this may be due to other factors than the endo-
crine treatment, such as lifestyle factors. The consequences 
of lower BMD for long-term bone health in these individ-
uals remains unclear. Future studies should evaluate peak 
bone mass in those who started treatment as adolescents 
and investigate clinically important outcomes such as frac-
ture risk in this population.
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